Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Efficacy and Safety of Chidamide+Sintilimab+Bevacizumab in Subjects With Advanced Extrapulmonary Neuroendocrine Carcinoma Who Have Failed First-Line Standard Therapy: A Single-Arm, Phase II, Multicenter Study

NCT07518602 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07518602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07518602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Efficacy and Safety of Chidamide+Sintilimab+Bevacizumab in Subjects With Advanced Extrapulmonary Neuroendocrine Carcinoma Who Have Failed First-Line Standard Therapy: A Single-Arm, Phase II, Multicenter Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
March 27, 2026
Completion date
September 27, 2028
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary neuroendocrine carcinoma (ep-nec)